STAT1 and lung adenocarcinoma: In addition to being a DNA synthesis inhibitor, fludarabine, acting as a selective Stat1 activation inhibitor [45], may be a potential therapeutic agent in combination therapy for lung adenocarcinoma by inhibiting the anti-apoptotic effects of Oct4.